Cloning

Cellular Biomedicine Group Announces Data to be Presented at 2020 ASH Annual Meeting

Retrieved on: 
Friday, December 4, 2020
Branches of biology, Biology, Life sciences, Biotechnology, Cell biology, Cloning, Developmental biology, Stem cell, Center for Cell and Gene Therapy

A copy of the presentation materials will be made available on the Investor Relations section of the Company website following the presentation.

Key Points: 
  • A copy of the presentation materials will be made available on the Investor Relations section of the Company website following the presentation.
  • Cellular Biomedicine Group, Inc. (Nasdaq: CBMG) develops proprietary cell therapies for the treatment of cancer and degenerative diseases.
  • The company conducts immuno-oncology and stem cell clinical trials in China using products from its integrated GMP laboratory.
  • The Company's GMP facilities in China, consisting of twelve independent cell production lines, are designed and managed according to both China and U.S. GMP standards.

India Stem Cell Market to 2026 by Product Type (Adult; Induced Pluripotent; Human Embryonic; Others), & Application (Regenerative Medicine Vs. Drug Discovery & Development) - ResearchAndMarkets.com

Retrieved on: 
Friday, November 27, 2020
Pharmaceutical, Genetics, Health, Stem cells, Branches of biology, Biology, Life sciences, Induced stem cells, Stem cells, Biotechnology, Developmental biology, Cloning, Tissue engineering, Stem-cell line

The "India Stem Cell Market by Product Type (Adult; Induced Pluripotent; Human Embryonic; Others), by Application (Regenerative Medicine Vs. Drug Discovery & Development), by Technology, by Region, Competition Forecast & Opportunities, FY 2026" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "India Stem Cell Market by Product Type (Adult; Induced Pluripotent; Human Embryonic; Others), by Application (Regenerative Medicine Vs. Drug Discovery & Development), by Technology, by Region, Competition Forecast & Opportunities, FY 2026" report has been added to ResearchAndMarkets.com's offering.
  • The Indian Stem Cell Market is expected to grow at over 12% CAGR during FY 2021 - FY 2026.
  • Continuous advancements in tissue engineering is one of the prime factors boosting the Indian Stem Cell Market.
  • The Indian Stem Cell Market is segmented based on product type, application, technology, and region.

FRANZ Skincare USA unveils groundbreaking Stem Cell Culture Medium Ampoule

Retrieved on: 
Thursday, November 19, 2020
Branches of biology, Biology, Life sciences, Biotechnology, Cell biology, Induced stem cells, Cloning, Developmental biology, Stem cell, Cell culture

NEW YORK, Nov. 19, 2020 /PRNewswire/ -- The pinnacle of at-home-skincare technology, the innovative Stem Cell Culture Medium Ampoule made with a10% concentration stem cell culture medium.

Key Points: 
  • NEW YORK, Nov. 19, 2020 /PRNewswire/ -- The pinnacle of at-home-skincare technology, the innovative Stem Cell Culture Medium Ampoule made with a10% concentration stem cell culture medium.
  • While FRANZ is known in the industry for high-tech and award-winning masks, Stem Cell Culture Medium Ampoule is an ultra-concentrated serum that minimizes the signs of aging, such as fine lines, wrinkles, hyperpigmentation, and loss of volume.
  • Perfect for a skin cleanse or boost before an event we recommend our Two- Week Repair and Reset program paring Bare Stem Cell Culture Medium Ampoule and FRANZ Premium Microcurrent Facial Dual Mask.
  • Stem Cell Culture Medium Ampoule is currently available on FRANZskincareusa.com at a suggested retail price of $15/ampoule.

Hope Biosciences Stem Cell Research Foundation Selects Phlexglobal to Support Rapid, Compliant Investigational New Drug Application for COVID-19 Therapy

Retrieved on: 
Tuesday, November 10, 2020
Branches of biology, Biology, Life sciences, Regenerative biomedicine, Emerging technologies, Biotechnology, Cloning, Developmental biology, Stem cell, Regenerative medicine, Rosetta Martiniello-Wilks, Susan L. Solomon

"We launched the Foundation this year to accelerate translational research in regenerative medicine so that therapies could be delivered to patients faster, ultimately by delivering high-quality data for quicker approval," noted Donna Chang, Founder, Hope Biosciences Stem Cell Research Foundation.

Key Points: 
  • "We launched the Foundation this year to accelerate translational research in regenerative medicine so that therapies could be delivered to patients faster, ultimately by delivering high-quality data for quicker approval," noted Donna Chang, Founder, Hope Biosciences Stem Cell Research Foundation.
  • If you need support for your research, Contact Phlexglobal today to receive COVID-19 study help tomorrow.
  • Hope Biosciences Stem Cell Research Foundation, administered through the Greater Houston Community Foundation, was founded to address the need to accelerate translational research in regenerative medicine so that therapies could be delivered to patients faster.
  • Today, the foundation is leading the effort in using mesenchymal stem cells to combat COVID-19, with three FDA approved protocols for coronavirus.

Magenta Therapeutics Announces Multiple Presentations Across Stem Cell Transplant Portfolio at The American Society of Hematology (ASH) Annual Meeting

Retrieved on: 
Wednesday, November 4, 2020
Health, Stem cells, Clinical trials, General Health, Pharmaceutical, Biotechnology, Branches of biology, Biology, Life sciences, Biotechnology, Cell biology, Cloning, Developmental biology, Stem cell, MGTA, American Society of Hematology

Magenta Therapeutics (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplant to more patients, today announced that data across the portfolio will be presented at the American Society of Hematology (ASH) annual meeting, to be held December 5-8, 2020.

Key Points: 
  • Magenta Therapeutics (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplant to more patients, today announced that data across the portfolio will be presented at the American Society of Hematology (ASH) annual meeting, to be held December 5-8, 2020.
  • All primary and secondary endpoints were met in the MGTA-145 Phase 1 trial in healthy volunteers completed earlier this year.
  • By the end of 2020, Magenta intends to initiate multiple Phase 2 clinical trials of MGTA-145.
  • Magenta is combining leadership in stem cell biology and biotherapeutics development with clinical and regulatory expertise, a unique business model and broad networks in the stem cell transplant world to revolutionize immune reset for more patients.

Sana Biotechnology Announces Acquisition of Oscine

Retrieved on: 
Friday, October 30, 2020
Branches of biology, Biology, Life sciences, Glial cells, Stem cells, Cloning, Developmental biology, Glia, Biotechnology, Progenitor cell, Draft:Steven Goldman

SEATTLE, Oct. 30, 2020 /PRNewswire/ -- Sana Biotechnology, Inc. (Sana), focused on creating and delivering engineered cells as medicines, announced today the acquisition ofOscine Corp., a company developing potentially curative or disease modifying cell therapies for diseases of the brain and central nervous system (CNS).

Key Points: 
  • SEATTLE, Oct. 30, 2020 /PRNewswire/ -- Sana Biotechnology, Inc. (Sana), focused on creating and delivering engineered cells as medicines, announced today the acquisition ofOscine Corp., a company developing potentially curative or disease modifying cell therapies for diseases of the brain and central nervous system (CNS).
  • "We are excited about the potential of the glial progenitor cell program Oscine has been developing to help patients with a number of different diseases of the brain.
  • Steve Goldman, M.D., Ph.D.,was Oscine's scientific founder and joins Sana as the Head of CNS Therapy.Dr.
  • Sana Biotechnology, Inc. is focused on creating and delivering engineered cells as medicines for patients.

AgeX Therapeutics Sublicenses Stem Cell Line ESI-053 to ImStem Biotechnology for Development of Cell Therapy Candidate IMS001 for COVID-19 and Acute Respiratory Distress Syndrome

Retrieved on: 
Wednesday, October 28, 2020
Biotechnology, Health, Stem cells, Pharmaceutical, Clinical trials, Branches of biology, Biology, Life sciences, Stem cells, Induced stem cells, Biotechnology, Cell biology, Cloning, Stem-cell line, Cell therapy, AgeX Therapeutics, ImStem Biotechnology, ES Cell International

This ultimately led to research and commercial sublicense agreements for the ESI-053 ESC line by ImStem to develop IMS001 as an allogeneic, off-the-shelf and industrially scalable MSC product candidate.

Key Points: 
  • This ultimately led to research and commercial sublicense agreements for the ESI-053 ESC line by ImStem to develop IMS001 as an allogeneic, off-the-shelf and industrially scalable MSC product candidate.
  • IMS001 is believed to be the first MSC product derived from an ESC line to be accepted for a human trial by the FDA.
  • We are glad to expand our relationship with ImStem, so it can now utilize AgeXs ESI-053 stem cell line to develop its cell therapy candidate IMS001 for COVID-19 as well as acute respiratory distress syndrome more broadly, said Dr. Nafees Malik, Chief Operating Officer of AgeX.
  • The ESI stem cell lines are distinguished as the first clinical-grade human pluripotent stem cell lines created under current Good Manufacturing Practice as described in Cell Stem Cell (2007;1:490-4).

BrainStorm Announces Scientific Presentation of NurOwn® Exosome Preclinical ARDS Outcomes at the Virtual New York Stem Cell Foundation Conference

Retrieved on: 
Monday, October 19, 2020
Branches of biology, Biology, Life sciences, Biotechnology, Cell biology, Cloning, Developmental biology, Stem cell

ARDS is caused by increased amounts of pro-inflammatory cytokines, leading to lung damage and loss of lung function.

Key Points: 
  • ARDS is caused by increased amounts of pro-inflammatory cytokines, leading to lung damage and loss of lung function.
  • The NYSCF Conference is the leading scientific meeting on translational stem cell research.
  • NurOwn (autologous MSC-NTF) cells represent a promising investigational therapeutic approach to targeting disease pathways important in neurodegenerative disorders.
  • BrainStorm Cell Therapeutics Inc. is a leading developer of innovative autologous adult stem cell therapeutics for debilitating neurodegenerative diseases.

One World Pharma Enters Agreement and LOI with BIOTROPICAL for Up to 600,000 Cuttings

Retrieved on: 
Friday, October 16, 2020
Asexual reproduction, Cloning, Plant reproduction, Cutting, Biology, Articles, LOI, Vegetative, Behavior

Additionally, the Companies have entered into a Letter of Intent (LOI) for BIOTROPICAL to purchase up to 600,000 cuttings from One World Pharma.

Key Points: 
  • Additionally, the Companies have entered into a Letter of Intent (LOI) for BIOTROPICAL to purchase up to 600,000 cuttings from One World Pharma.
  • A plant cutting is a part of a plant that is used in horticulture for vegetative (asexual) propagation, in this instance cannabis production.
  • Under the terms of the LOI, One World Pharma would purchase the entire harvest from BIOTROPICAL.
  • After the initial 30,000 cuttings, BIOTROPICAL plans to expand its operation up to 600,000 cuttings by the second quarter of 2021.

Qihan Biotech Unveils its Program to Develop Immunologically Privileged Human Stem Cells for Allogeneic Cell Therapies

Retrieved on: 
Wednesday, October 14, 2020
Science, Stem cells, Biotechnology, Research, Pharmaceutical, Oncology, Health, Genetics, Branches of biology, Biology, Life sciences, Stem cells, Biotechnology, Cell biology, Cloning, Induced stem cells, Cell therapy, Shimon Slavin

Qihan Biotech, a leader in applying multiplexable genome editing technology to cell therapies and organ transplantation, today disclosed the initiation of a program to create immunologically privileged human stem cells to enable the development of improved allogeneic cell therapies.

Key Points: 
  • Qihan Biotech, a leader in applying multiplexable genome editing technology to cell therapies and organ transplantation, today disclosed the initiation of a program to create immunologically privileged human stem cells to enable the development of improved allogeneic cell therapies.
  • Once differentiated into different cell types, the cells have the potential to be used as universal, allogeneic therapies while reducing or eliminating the need for the patient to receive immunosuppressive drugs.
  • To address these obstacles and realize the full potential of allogeneic cell therapies, the Qihan team is using our proprietary multiplexable gene editing technology, in combination with our extensive expertise in transplantation immunology, to create immunologically privileged human stem cells.
  • Qihan Biotech is a biotechnology company applying genome-editing technology to develop novel cell therapies and organs for transplantation.